liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Combination of pegylated IFN-alpha 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia
Uppsala University.
Oslo University Hospital.
Umea University.
Turku University Hospital.
Show others and affiliations
2011 (English)In: Blood, ISSN 0006-4971, E-ISSN 1528-0020, Vol. 118, no 12, 3228-3235 p.Article in journal (Refereed) Published
Abstract [en]

Biologic and clinical observations suggest that combining imatinib with IFN-alpha may improve treatment outcome in chronic myeloid leukemia (CML). We randomized newly diagnosed chronic-phase CML patients with a low or intermediate Sokal risk score and in imatinib-induced complete hematologic remission either to receive a combination of pegylated IFN-alpha 2b (Peg-IFN-alpha 2b) 50 mu g weekly and imatinib 400 mg daily (n = 56) or to receive imatinib 400 mg daily monotherapy (n = 56). The primary endpoint was the major molecular response (MMR) rate at 12 months after randomization. In both arms, 4 patients (7%) discontinued imatinib treatment (1 because of blastic transformation in imatinib arm). In addition, in the combination arm, 34 patients (61%) discontinued Peg-IFN-alpha 2b, most because of toxicity. The MMR rate at 12 months was significantly higher in the imatinib plus Peg-IFN-alpha 2b arm (82%) compared with the imatinib monotherapy arm (54%; intention-to-treat, P = .002). The MMR rate increased with the duration of Peg-IFN-alpha 2b treatment (andlt; 12-week MMR rate 67%, andgt; 12-week MMR rate 91%). Thus, the addition of even relatively short periods of Peg-IFN-alpha 2b to imatinib markedly increased the MMR rate at 12 months of therapy. Lower doses of Peg-IFN-alpha 2b may enhance tolerability while retaining efficacy and could be considered in future protocols with curative intent.

Place, publisher, year, edition, pages
American Society of Hematology , 2011. Vol. 118, no 12, 3228-3235 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-71380DOI: 10.1182/blood-2011-02-336685ISI: 000295120900009OAI: diva2:448062
Funding Agencies|European LeukemiaNet||Novartis Pharma||Merck & Co (formerly Schering-Plough)||Regional Oncological Center, University of Uppsala||Novartis||BMS||Available from: 2011-10-14 Created: 2011-10-14 Last updated: 2011-10-14

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Malm, Claes
By organisation
OncologyFaculty of Health SciencesDepartment of Haematology UHL
In the same journal
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 36 hits
ReferencesLink to record
Permanent link

Direct link